Lung cancer: First-line immunotherapy in lung cancer — taking the first step

Nature Reviews Clinical Oncology. doi:10.1038/nrclinonc.2016.148

Authors: Stephen V. Liu & Giuseppe Giaccone

The use of programmed cell-death protein 1 (PD-1) inhibitors has become the standard-of-care approach for patients with advanced-stage, previously treated non-small-cell lung cancer. The inevitable adoption of these agents in the first-line setting is rapidly approaching, but the optimal strategy remains unclear. Two published clinical trial reports, examining different approaches, help to frame this question.

http://ift.tt/2cso1dA